Axitinib Induces Paradoxical Erythropoietin Synthesis in Metastatic Renal Cell Carcinoma REPLY

被引：1
作者：
Alexandrescu, Doru T. [1 ]
Dasanu, Constantin A. [2 ]
机构：
[1] Georgetown Univ, Div Hematol & Oncol, Washington, DC USA
[2] St Francis Hosp & Med Ctr, Dept Hematol Oncol, Hartford, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 03期
关键词：
ACUTE MYELOID-LEUKEMIA; SUNITINIB; VEGF; INHIBITORS; SU5416; AGENT;
D O I：
10.1200/JCO.2008.20.2366
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：473 / 474
页数：3
相关论文
共 10 条
[1]   Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib [J].
Alexandrescu, Doru T. ;
McClure, Rebecca ;
Farzanmehr, Haleh ;
Dasanu, Constantin A. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (24) :4047-4048
[2]   Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins [J].
DePrimo, Samuel E. ;
Bello, Carlo L. ;
Smeraglia, John ;
Baum, Charles M. ;
Spinella, Dominic ;
Rini, Brian I. ;
Michaelson, M. Dror ;
Motzer, Robert J. .
JOURNAL OF TRANSLATIONAL MEDICINE, 2007, 5
[3]   A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia [J].
Fiedler, W ;
Mesters, R ;
Tinnefeld, H ;
Loges, S ;
Staib, P ;
Dührsen, U ;
Flasshove, M ;
Ottmann, OG ;
Jung, WF ;
Cavalli, F ;
Kuse, R ;
Thomalla, J ;
Serve, H ;
O'Farrell, AM ;
Jacobs, M ;
Brega, NM ;
Scigalla, P ;
Hossfeld, DK ;
Berdel, WE .
BLOOD, 2003, 102 (08) :2763-2767
[4]   VEGF inhibitors make blood [J].
Fischer, Christian ;
Carmeliet, Peter ;
Conway, Edward M. .
NATURE MEDICINE, 2006, 12 (07) :732-734
[5]   The anti-angiogenesis agent, AG-013736, has minimal activity in elderly patients with poor prognosis acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) [J].
Giles, FJ ;
Bellamy, WT ;
Estrov, Z ;
O'Brien, SM ;
Verstovsek, S ;
Ravandi, F ;
Beran, M ;
Bycott, P ;
Pithavala, Y ;
Steinfeldt, H ;
Reich, SD ;
List, AF ;
Yee, KWL .
LEUKEMIA RESEARCH, 2006, 30 (07) :801-811
[6]   Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas [J].
Heymach, JV ;
Desai, J ;
Manola, J ;
Davis, DW ;
McConkey, DJ ;
Harmon, D ;
Ryan, DP ;
Goss, G ;
Quigley, T ;
Van den Abbeele, AD ;
Silverman, SG ;
Connors, S ;
Folkman, J ;
Fletcher, CDM ;
Demetri, GD .
CLINICAL CANCER RESEARCH, 2004, 10 (17) :5732-5740
[7]   Paradoxical secondary polycythemia in von Hippel-Lindau patients treated with anti-vascular endothelial growth factor receptor therapy [J].
Richard, S ;
Croisille, L ;
Yvart, J ;
Casadeval, N ;
Eschwège, P ;
Aghakhani, N ;
David, P ;
Gaudric, A ;
Scigalla, P ;
Hermine, O .
BLOOD, 2002, 99 (10) :3851-3853
[8]   Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma [J].
Rini, Brian I. ;
Michaelson, M. Dror ;
Rosenberg, Jonathan E. ;
Bukowski, Ronald M. ;
Sosman, Jeffrey A. ;
Stadler, Walter M. ;
Hutson, Thomas E. ;
Margolin, Kim ;
Harmon, Charles S. ;
DePrimo, Samuel E. ;
Kim, Sindy T. ;
Chen, Isan ;
George, Daniel J. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) :3743-3748
[9]   Axitinib for renal cell carcinoma [J].
Sonpavde, Guru ;
Hutson, Thomas E. ;
Rini, Brian I. .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2008, 17 (05) :741-748
[10]   VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis [J].
Tam, Betty Y. Y. ;
Wei, Kevin ;
Rudge, John S. ;
Hoffman, Jana ;
Holash, Joceyln ;
Park, Sang-ki ;
Yuan, Jenny ;
Hefner, Colleen ;
Chartier, Cecile ;
Lee, Jeng-Shin ;
Jiang, Shelly ;
Niyak, Nihar R. ;
Kuypers, Frans A. ;
Ma, Lisa ;
Sundram, Uma ;
Wu, Grace ;
Garcia, Joseph A. ;
Schrier, Stanley L. ;
Maher, Jacquelyn J. ;
Johnson, Randall S. ;
Yancopoulos, George D. ;
Mulligan, Richard C. ;
Kuo, Calvin J. .
NATURE MEDICINE, 2006, 12 (07) :793-800
1